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ABSTRACT
Tumour angiogenesis has long been a focus of anti-cancer therapy;
however, anti-angiogenic cancer treatment strategies have had limited
clinical success. Tumour-associatedmyeloid cells are believed to play
a role in the resistance of cancer towards anti-angiogenesis therapy,
but the mechanisms by which they do this are unclear. An embryonic
zebrafish xenograft model has been developed to investigate the
mechanisms of tumour angiogenesis and as an assay to screen anti-
angiogenic compounds. In this study, we used cell ablation techniques
to remove either macrophages or neutrophils and assessed their
contribution towards zebrafish xenograft angiogenesis by quantitating
levels of graft vascularisation. The ablation of macrophages, but
not neutrophils, caused a strong reduction in tumour xenograft
vascularisation and time-lapse imaging demonstrated that tumour
xenograft macrophages directly associated with the migrating tip of
developing tumour blood vessels. Finally, we found that, although
macrophages are required for vascularisation in xenografts that either
secrete VEGFA or overexpress zebrafish vegfaa, they are not required
for the vascularisation of grafts with low levels of VEGFA, suggesting
that zebrafish macrophages can enhance Vegfa-driven tumour
angiogenesis. The importance of macrophages to this angiogenic
response suggests that this model could be used to further investigate
the interplay between myeloid cells and tumour vascularisation.
KEY WORDS: Macrophage, Angiogenesis, Zebrafish, Tumour,
Xenograft
INTRODUCTION
Angiogenesis has been a focus of cancer research due to its
importance for tumour growth and metastasis (Hanahan and
Weinberg, 2011; Presta et al., 1997; Huang et al., 2010). The
tumour vasculature often appears as a disorganised network of
permeable and irregularly shaped vessels and arises through a range
of mechanisms, which include the induction of sprouting
angiogenesis, endothelial progenitor-mediated vasculogenesis and
the co-option of existing vessels (Krishna Priya et al., 2016). Many
angiogenesis inhibitor drugs have targeted vascular endothelial
growth factor (VEGF) signalling, a pathway that plays a key role in
both developmental and disease-associated angiogenesis by
stimulating the proliferation and migration of endothelial cells
(Lee et al., 2015; Sennino and McDonald, 2012; Ye, 2016).
However, VEGF inhibitors have had limited clinical success, with
the cancer often relapsing after an initial period of remission
(Carrato et al., 2013; Robert et al., 2011; Casanovas et al., 2005;
Ferrara, 2010).
Inflammation can also drive tumour angiogenesis (Marelli et al.,
2017), with the presence of leukocytes in the tumour region being
positively correlated with levels of tumour vascularisation and
associated with poor patient prognosis (Granot and Jablonska,
2015; Sionov et al., 2015; Mantovani et al., 2017). Macrophages
and neutrophils can also promote angiogenesis in a variety of other
settings, such as during developmental angiogenesis and in post-
ischaemic neovascularisation (Fantin et al., 2010; Ohki et al., 2005).
Macrophages have been shown to drive tumour vascularisation in
mouse models (Piaggio et al., 2016; De Palma et al., 2003; Lin et al.,
2006) and the depletion of tumour-associated macrophages results
in an improved response to drugs targeting the VEGFR pathway,
suggesting that macrophages aid in the escape from VEGFR
inhibition (Shojaei et al., 2009; Zhang et al., 2010). Tumour-
associated macrophages appear to stimulate angiogenesis by either
direct or indirect mechanisms that increase the levels of
pro-angiogenic factors (such as VEGF, HIF-1α and CCL18) (Guo
et al., 2016; Lewis et al., 2016; Noy and Pollard, 2014; Deryugina
and Quigley, 2010) or by transdifferentiation into endothelial-like
cells that are capable of forming tubular structures (Asahara et al.,
1997; Chen et al., 2009; Coukos et al., 2007). Neutrophils have also
been shown to promote tumour angiogenesis, particularly via the
production of MMP-9 (Nozawa et al., 2006; Uribe-Querol and
Rosales, 2015; Ardi et al., 2009).
The embryonic zebrafish tumour xenograft model exploits the
optical transparency of the zebrafish embryo and the availability of
fluorescent blood vessel reporter lines to study the process of
tumour angiogenesis. The model involves implanting tumour cells
into the perivitelline space of a 2-day-old zebrafish embryo and
observing the angiogenic response over the next 2 days (Nicoli and
Presta, 2007). The blood vessels that grow into the xenograft have
been shown to form an abnormal network of varying vessel
morphology typical of mammalian tumours (Zhao et al., 2011a).
The xenograft can be imaged in vivo, allowing observation of the
mechanisms driving tumour vascularisation, such as sprouting
angiogenesis, vascular co-option and endothelial cell migration
(Zhao et al., 2011a,b), and can be used to screen for novel
anti-angiogenesis drugs (Okuda et al., 2016). Despite the successes
of this model, the precise role of the xenografted tumour cells and
tumour-associated immune cells, with respect to the stimulation
of angiogenesis, has not yet been determined. As zebrafish
macrophages have previously been shown to be required for
inflammatory lymphangiogenesis and to express pro-angiogenicReceived 6 June 2018; Accepted 25 October 2018
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vegf ligands (Okuda et al., 2015), this led us to investigate the role of
macrophages in the zebrafish embryo tumour xenograft model of
tumour angiogenesis.
In this study, we found that VEGFR-dependent angiogenesis
occurs upon implantation of tumour cells or non-tumour cells into
zebrafish embryos and that, although neutrophils and macrophages
are recruited to these grafts, only macrophages have a role in tumour
xenograft angiogenesis. Live-imaging analysis demonstrates that
macrophages associate with developing tumour xenograft blood
vessels, suggesting that they are directly mediating angiogenesis.
We also showed that macrophages are required for angiogenesis
when VEGFA/vegfaa-secreting cells are xenografted, but not in
grafts with low levels of VEGFA secretion, suggesting that
macrophages have a role in enhancing Vegfa-driven angiogenesis.
These findings demonstrate that embryonic zebrafish xenografts can
model macrophage-mediated angiogenesis and can be used to
provide insights into the interface between innate immunity and
tumour vascularisation.
RESULTS
Angiogenic and immune responses are observed upon
graft implantation
To study the role of innate immune cells during tumour angiogenesis,
we implanted either B16-F1 mouse melanoma cells, MDA-MB-231
human breast cancer cells, HEK-293T human embryonic kidney cells
or abiotic Fluosphere beads into the perivitelline space of embryos at
2 days post-fertilisation (dpf) (Fig. 1A). We quantitated graft
vascularisation by live imaging larvae at 2 days post-injection (dpi)
and establishing the percentage volume of the graft that was occupied
by GFP-expressing blood vessels. Using this method, we found the
B16-F1 grafts displayed the highest level of vascularisation, followed
by MDA-MB-231 cells. Surprisingly, both HEK-293T and
Fluosphere grafts also induced vascularisation, albeit to a lower
level than the cancer cell lines (Fig. 1B-F). The quantity of VEGFA
secreted by the three cell lines was also assessed, and it was found that
it positively correlated with their levels of vascularisation: B16-F1
cells secreted the highest levels of VEGFA, followed by the
MDA-MB-231 cells and lastly the HEK-293T cells (Fig. 1G). In
support of VEGFR signalling being required for graft angiogenesis,
vascularisation in all three grafts was inhibited by the VEGFR
inhibitor tivozanib (Fig. 1H) (Nakamura et al., 2006; Okuda et al.,
2015). FGF signalling has also been implicated in zebrafish graft
vascularisation (Nicoli et al., 2007), but treatment with the FGF/
VEGFR co-inhibitor SU5402 (Sun et al., 1999), either alone or in
combination with tivozanib, did not further inhibit graft
vascularisation when compared to tivozanib treatment alone
(Fig. 1H), suggesting that FGF signalling is not a major driver of
angiogenesis in this model.
We next assessed innate immune cell recruitment to the grafts by
counting either mpeg-expressing macrophages (Ellett et al., 2011)
or mpx-expressing neutrophils (Lieschke et al., 2001; Renshaw
et al., 2006; Okuda et al., 2015) within the graft at 6 h post-injection
(hpi), 24 hpi and 48 hpi. All graft types recruited both macrophages
and neutrophils (Fig. 2 and Fig. S1), with macrophage numbers
peaking at 6 hpi. B16-F1 grafts displayed the highest number of
macrophages at this timepoint, with the MDA-MB-231 and
HEK-293T xenografts displaying similar levels of macrophage
recruitment, while the Fluosphere grafts had the lowest levels
(Fig. 2). These findings were also observed when we normalised
macrophage recruitment against graft volume, although the
HEK-293T xenografts showed a level of macrophage recruitment
more similar to the B16-F1 grafts by this measure (Fig. 2F).
Macrophages contribute to tumour xenograft
vascularisation
Given that all graft types could induce both immune cell recruitment
and vascularisation, we wondered whether leukocytes had a role in
the angiogenic response. We conducted clodronate-mediated
macrophage ablation to specifically induce macrophage death in
grafted larvae (Hall et al., 2018; Astin et al., 2017; Carrillo et al.,
2016; Lai et al., 2017). The efficacy of macrophage reduction was
assessed by measuring the difference in the number of
graft-associated macrophages in larvae injected with clodronate-
containing liposomes and larvae injected with PBS-containing
liposomes. Clodronate-mediated macrophage ablation produced a
reduction in graft-associated macrophages of at least 40% by 6 hpi,
60% by 24 hpi and 70% by 48 hpi (Fig. 3A-I), did not alter the level
of neutrophil recruitment to the graft (Fig. S2A), and resulted in a
50% reduction in tumour vascularisation in both the MDA-MB-231
and B16-F1 xenografts at 48 hpi (Fig. 3A-H,J). In contrast, both
HEK-293T and Fluosphere grafts displayed no difference in
vascularisation at 48 hpi when subjected to macrophage ablation
(Fig. 3A-H,J), suggesting that macrophages only have a role in the
vascularisation of tumour xenografts.
In the embryos subjected to macrophage ablation, the main
difference in the tumour xenograft vasculaturewas a reduction in the
number of vessels growing inside the tumour region and the depth to
which these vessels penetrated the tumour mass compared to the
control fish. This was most obvious in the B16-F1 xenografts, where
the control tumours often had a rich network of blood vessels
growing through the entire xenograft, while the embryos subjected
to ablation only showed a few vessels forming in a localised part of
the xenograft (Movies 1 and 2).
To confirm the effect of macrophage ablation on tumour xenograft
vascularisation, we also employed nitroreductase-mediated
macrophage ablation on the MDA-MB-231-xenografted Tg(mpeg1:
NTR:mcherry) larvae by treating them with 5 mM metronidazole
(Okuda et al., 2015; Petrie et al., 2014). Graft-associated
macrophages were reduced by 40% at 6 hpi and 60% at 24 hpi,
and xenograft vascularisation was reduced by more than 40% in the
embryos incubated in metronidazole compared with the embryos
incubated in DMSO (Fig. S3). Overall, using both clodronate- and
nitroreductase-mediated ablation, we have shown that macrophages
drive vascularisation of tumour xenografts in zebrafish embryos.
As neutrophil recruitment was also observed in the tumour
xenografts, we sought to assess the contribution of neutrophils by
observing the effects of their removal via nitroreductase-mediated
ablation in Tg(mpx:NTR:mCherry) larvae. Despite reducing
graft-associated neutrophil numbers by 35% at 6 hpi and 75% at
1 dpi, no significant difference was seen in graft vascularisation at
2 dpi (Fig. S4), suggesting that neutrophils do not have a significant
role in graft vascularisation. Importantly, metronidazole, the
pro-drug used in nitroreductase-mediated ablation, did not have
any effect on the level of macrophage or neutrophil recruitment or
on graft vascularisation when administered to larvae lacking the
nitroreductase enzyme (Fig. S2B-D).
Macrophages associate with growing tumour vessels
Given that macrophages have a role in angiogenesis within tumour
xenografts, we sought to observe their behaviour during the
angiogenic process. Time-lapse imaging of angiogenesis in the
MDA-MB-231 and B16-F1 tumour xenografts was conducted from
8 hpi and we consistently observed macrophages interacting with
the blood vessels growing within the xenograft (Fig. 4A-G,
Movies 3 and 4). Specifically, we saw an increased presence of
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tumour-xenograft-associated macrophages at the distal tips of
xenograft blood vessels.
To confirm the significance of the macrophage–vessel
interactions, we quantitated the association of graft macrophages
with the vascular tips. We measured macrophage presence in a
10 μm circle centred at the tip of a growing vessel (angiogenic
region) and compared this with a control region of the same size
located at a constant distance from the vascular tip (Fig. 4A-H,
Fig. 1. Graft implantation induces an angiogenic response. (A) Schematic indicating the location of the implanted graft (green) in the perivitelline space of
a zebrafish embryo. (B-E) Confocal images of kdrl:EGFP-expressing blood vessels (green) in zebrafish embryo grafts (white dashed line) at 2 dpi.
(F) Quantitation of graft vascularisation at 2 dpi, n>18. (G) Quantitation of secreted VEGFA levels, n=2. (H) Quantitation of graft vascularisation in embryos
incubated in either 0.5% DMSO, 50 nM Tivozanib, 200 nM SU5402 or 50 nM Tivozanib+200 nM SU5402, n>14. Error bars represent s.d. n.s, P>0.05;
**P<0.01 by one-way ANOVA. Scale bar: 50 µm.
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described in detail in the Materials and Methods). We found that
macrophages were more commonly present at or near the tips of
these developing tumour vessels than in the avascular control
regions (Fig. 4I) and that there were also more macrophages located
at the tips of the vessels compared to avascular regions (Fig. 4J),
suggesting that macrophages play a direct role in xenograft
angiogenesis. We defined a ‘tip cell’ macrophage as one that
associated with a distal tip of a developing graft blood vessel for at
least 40 min, and identified 12 tip cell macrophages from our time-
lapse movies of MDA-MB-231 and B16-F1 grafts. Tip cell
macrophages associated with the graft blood vessel for an average
of 69 min and, during this time, ceased active migration and
maintained contact with the vessel tip, only resuming normal
macrophage migratory behaviour once they had dissociated from
the vessel (Fig. 4K-U). We also tracked tip cell macrophages both
before and after their association with a vessel and this revealed that
only 3/11 tip cell macrophages made an association with another
blood vessel tip, suggesting that there is a large pool of potential ‘tip
cell macrophages’ within the graft.
Macrophages are required for effective angiogenesis
induced by graft-expressed vegfaa
As the cancer cells in our xenografts express VEGFA (Fig. 1G) and
xenograft vascularisation is sensitive to inhibition of VEGFR
signalling (Fig. 1H), this led us to hypothesise that the xenograft-
associated macrophages can potentiate tumour angiogenesis that is
driven by xenograft-supplied VEGFA. To test this hypothesis, we
developed both HEK-293T andMDA-MB-231 cell lines that express
a zebrafish ortholog of VEGFA (vegfaa). The cell lines transfected
with the zf-vegfaa-expression vector were confirmed to express
vegfaa by reverse-transcription PCR (RT-PCR) (Fig. S5A) and,
when xenografted in zebrafish embryos, both HEK-293T–vegfaa
and MDA-MB-231–vegfaa xenografts displayed a level of
vascularisation significantly higher than the control lines
(Fig. 5A-E), while macrophage recruitment in the vegfaa-
expressing xenografts was similar to the control (Fig. S5B-G).
Clodronate-mediated macrophage ablation was shown to be effective
in xenografts of both vegfaa-expressing cell lines, resulting in a
reduction of graft-associatedmacrophages of at least 50% at 6 hpi and
80% at 24 hpi (Fig. S5H,I). Importantly, macrophage ablation caused
a 40% reduction in the level of vascularisation in bothHEK-293Tand
MDA-MB-231 vegfaa-expressing xenografts (Fig. 5F-N), supporting
our hypothesis that macrophages are required for effective
angiogenesis in grafts expressing vegfaa.
The graft vessels predominantly form by sprouting from the
common cardinal vein (CCV). We found that the vegfaa-expressing
xenografts appeared to induce a very strong angiogenic response,
with vessels present throughout the volume of the xenograft. By
contrast, in the embryos subjected to macrophage ablation, xenograft
vessels were proximal to the CCV and either did not extend distally
into the tumour or only grew into the superficial layers of the
xenograft (Movies 5-8). The extent of graft vascularisation was
quantitated by dividing the graft into equal thirds (proximal to the
CCV, middle and distal to the CCV) and quantitating the level of
Fig. 2. Macrophages are recruited to grafts. (A-D) Confocal images of mpeg1:mCherry-expressing macrophages (red) in zebrafish embryo grafts (blue) at
6 hpi. (E) Quantitation of graft-associated macrophages at 6, 24 and 48 hpi, n>14. (F) Quantitation of graft-associated macrophages normalised for graft volume
at 6 hpi, n>16. Error bars represent s.d. n.s, P>0.05; **P<0.01 by one-way ANOVA. Scale bar: 50 µm.
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vascularisation within each of these subsections (Fig. 5O). We found
that, while the grafts in macrophage-ablated embryos had similar
levels of proximal vascularisation, the middle and distal thirds of the
graft had significantly lower levels of vascularisation when compared
to control (Fig. 5P).
Macrophages are not required for vascularisation of
MDA-MB-231 xenografts depleted of VEGFA
To determinewhether the role ofmacrophages in graft vascularisation
was confined to angiogenesis driven by xenograft-supplied
VEGFA, we used siRNA to knock down VEGFA in MDA-MB-
231 cells. We achieved an 85% reduction in the levels of secreted
VEGFA in siRNA-treated cells (Fig. 6A) which resulted in a 50%
reduction in graft vascularisation when compared to control
siRNA-treated cells (Fig. 6B,C,F), while the levels of graft-
associated macrophages remained unchanged (Fig. 6D,E,G).
When macrophages were ablated with clodronate, the level of
graft vascularisation remained unchanged (Fig. 6H-M), suggesting
that macrophages are not required for angiogenesis in tumour
xenografts with low levels of VEGFA.
Fig. 3. Macrophages contribute to tumour xenograft vascularisation. (A-H) Confocal images of mpeg1:mCherry-expressing macrophages (red) and kdrl:
EGFP-expressing blood vessels (green) in zebrafish embryo grafts (white dashed line) at 2 dpi that have been injected with either PBS-containing liposomes
(A-D) or clodronate-containing liposomes (E-H). (I) Quantitation of graft-associated macrophages at 6, 24 and 48 hpi with either PBS-containing or
clodronate-containing liposomes, n>10. (J) Quantitation of graft vascularisation at 2 dpi, n>16. Error bars represent s.d. n.s, P>0.05; **P<0.01 by t-test.
Scale bar: 50 µm.
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Fig. 4. See next page for legend.
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DISCUSSION
The zebrafish embryo tumour xenograft model has been developed
as an alternative to rodent and chick xenografts for the investigation
of tumour angiogenesis (Brown et al., 2017). The model was first
described in 2007 (Nicoli et al., 2007) and, since then, it has been
used to further the knowledge of the mechanisms of tumour
angiogenesis: identifying genes of interest, determining the cellular
processes involved in tumour angiogenesis and elucidating the
functions carried out by tumour blood vessels (Vlecken and
Bagowski, 2009; Zhao et al., 2016, 2011b). The main strengths of
this model are the ability to image tumour angiogenesis in vivo and
the applicability for drug screening (Harfouche et al., 2009; Yang
et al., 2014a,b; Muthukumarasamy et al., 2016; Zhao et al., 2011b,
2016). While this model has gained popularity, the exact
mechanisms that underpin xenograft angiogenesis in zebrafish are
still unclear. In this study, we found that the angiogenic response
observed in zebrafish tumour xenografts has an inflammatory-
driven component and that macrophages are required for effective
angiogenesis within VEGFA/vegfaa-producing xenografts.
We used 3D-image analysis of the graft to quantitate tumour
vascularisation (Astin et al., 2014), which allowed us to determine
the angiogenic potential of different grafts and the effects of
different treatment strategies on the angiogenic response. In
the original description of this model, Nicoli et al., (2007) found
that certain non-tumour mammalian cell lines do not induce
an angiogenic response; however, we observed a modest angiogenic
response in non-tumour cell lines and even upon implantation of
an abiotic Fluosphere graft. This discrepancy can be explained
by the fact that we performed a quantitative analysis of graft
vascularisation, whereas previous studies had used less-sensitive
qualitative analyses to measure the angiogenic effects of
implantation of non-tumour cell lines (Nicoli et al., 2007).
Because of this, we propose that quantitative analyses, such as the
one described in this study, should be considered in future studies
using this model.
Our observations of macrophage and neutrophil recruitment are
consistent with other studies using this model (Yang et al., 2013; He
et al., 2012; Sanderson et al., 2015). We observed macrophage and
neutrophil recruitment within the tumour and non-tumour
xenografts, as well as in the Fluosphere grafts. This recruitment
appeared to follow a pattern of increasing leukocyte numbers over
the first 6 hpi (data not shown) and a subsequent decrease in
macrophage numbers over the next 2 dpi, demonstrating early and
high levels of leukocyte recruitment to the grafts. We used both
clodronate liposomes and nitroreductase-mediated cell ablation
to reduce macrophage number, and obtained quantitative
measurements in xenograft vascularisation. We found that
macrophages were required for effective vascularisation of
xenografts that expressed either VEGFA or zebrafish vegfaa, with
a dramatic decrease in vascularisation observed when macrophages
were ablated from either VEGFA-expressing xenografts (B16-F1 or
MDA-MB-231) or in xenografts that overexpressed vegfaa. Our
data support previous evidence of macrophage involvement in
zebrafish graft vascularisation that was based on qualitative
observations of reduced vascularisation upon inhibition of the
myeloid lineage using a spi1b morpholino (He et al., 2012). Our
findings also support studies in murine models, where the addition
or deletion of macrophages results in a respective increase or
decrease in tumour vascularisation (De Palma et al., 2003, 2005; Lin
et al., 2006), and human tumours, where macrophage presence has
been correlated with increased tumour angiogenesis and poor
patient prognosis (Heusinkveld and van der Burg, 2011).
The high level of macrophages within the poorly vascularised
HEK-293T xenografts indicates that the presence of graft-associated
macrophages is not sufficient to induce high levels of angiogenesis.
We also demonstrate that macrophages are only required for graft
vascularisation when the graft cells express VEGFA/vegfaa: in
contrast to the VEGFA-expressing B16-F1 and MDA-MB-231
tumour xenografts, in either Fluosphere or HEK-293T grafts, which
respectively express either no VEGFA or low levels of VEGFA,
macrophages had no detectable role in graft vascularisation.
In addition, we show that macrophages are not required for
vascularisation of MDA-MB-231 xenografts that are depleted in
VEGFA levels, while, conversely, macrophages are required for
vascularisation of HEK-293T grafts that overexpress vegfaa. Taken
together, these data suggest that there may be differences in the
angiogenic potential of graft macrophages between the different
graft types and that this relates to the differing levels of VEGFA
secretion from the grafts. One possibility is that there is a threshold
level of VEGFA/vegfaa that is required for macrophages to become
pro-angiogenic and, in support of this, there is evidence that
VEGFA can influence the activation state of mammalian
macrophages (Kloepper et al., 2016; Wheeler et al., 2018).
Another, perhaps more likely, possibility is that a base level of
graft angiogenesis is required before any pro-angiogenic
macrophage function can become evident in our assay;
pro-angiogenic macrophages can enhance vessel migration and
promote vascularisation but they may be unable to stimulate new
vessel sprouts de novo and therefore a macrophage-extrinsic
angiogenic stimulus is required (such as graft-supplied VEGFA/
vegfaa) before macrophages can promote vessel growth.
It is known that macrophages can exist in a diverse range of
phenotypes, with the broadest classification dividing them into
M1-like (which are more oriented towards a pathogen-fighting role)
and M2-like (more oriented towards a tissue repair and
immunosuppressive role) categories (Albini et al., 2018). The
pro-angiogenic macrophages that are present in tumours are
generally of the M2-like category, although they display a
diversity not entirely reflective of the M1/M2 dichotomy and exist
Fig. 4. Macrophages associate with developing xenograft vessels.
(A-G) Still images showing an MDA-MB-231 xenograft (A-D, Movie 3) or a
B16-F1 xenograft (E-G,Movie 4) in an embryowithmpeg1:mCherry-expressing
macrophages (red) and kdrl:EGFP-expressing blood vessels (green).
Individual macrophages associated with the angiogenic region (yellow dashed
circle) are indicatedwith yellowarrowheads, whilemacrophages associatedwith
the control region (cyan dashed circle) are indicated with cyan arrowheads.
The tumour region is outlined by a white dashed line in A and E. (H) Schematic
demonstrating the positioning of the 10-μm angiogenic region (dashed yellow
outline) at the tip of the blood vessel (green) and the control 10-μmcontrol region
(dashed cyan outline). (I) Quantitation of the percentage of frames during which
amacrophagewas observed at either an angiogenic region or a control region in
MDA-MB-231 and B16-F1 xenografts, n=3. (J) Mean number of macrophages
observed during each frame, in either the angiogenic region or the control
region, inMDA-MB-231 and B16 F1 xenografts, n=3. (K-R) Still images showing
a B16-F1 xenograft (Movie 4) in an embryo with mpeg1:mCherry-expressing
macrophages (red) and kdrl:EGFP-expressing blood vessels (green). An
individual macrophage (yellow arrowhead) is tracked for 1 h 10 min during (K-N)
and after (O-R) associating with the distal tip of a growing vessel (indicated by a
cyan arrowhead). (S,T) Macrophagemigration tracks of 12macrophages during
their period of contact with the tip of a growing vessel (S) and of the same
macrophages once they leave the vessel tip (T). Each macrophage is depicted
with the same colour in both S and T and they were tracked for identical periods
of time during contact and post-contact. (U) Quantitation of macrophage
migration speed during and after the period of contact with the tip of a growing
vessel, n=12. Error bars represent s.d. *P<0.05, **P<0.01 by t-test.
Scale bars: 50 µm.
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Fig. 5. See next page for legend.
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in subcategories such as the Tie2-expressing macrophages, which
have been shown to be highly adept at promoting angiogenesis and
other pro-tumour functions (Squadrito and De Palma, 2011). It is
possible that cytokines produced by tumour xenografts (such as
M-CSF, IL-10 and TGF-β) activate macrophages that migrate to the
xenograft, and contribute to their polarisation to a pro-angiogenic
phenotype (Galdiero et al., 2013). In zebrafish, embryonic
macrophages have recently been demonstrated to play a role in
both developmental and wound angiogenesis, although,
surprisingly, these macrophages appear to be identified by the
classical M1 marker Tnfα, highlighting the complexity of
pro-angiogenic macrophage phenotypes (Gerri et al., 2017;
Gurevich et al., 2018). The identity of the pro-angiogenic
macrophages in this model could be investigated by the use of
zebrafish transgenics that differentially label macrophages of
different phenotypes (Kanther et al., 2011; Nguyen-Chi et al.,
2015; Gerri et al., 2017).
The mechanism by which the pro-angiogenic zebrafish
macrophages enhance xenograft vascularisation is unclear. Our
time-lapse imaging data suggest that the role of macrophages
involves their direct interaction with the developing blood vessel; we
observed that macrophages frequently associated with the distal tips
of developing xenograft blood vessels. In addition, our observation
of limited endothelial cell penetration into the tumour region upon
the ablation of macrophages suggests that macrophages may be
assisting with the development of blood vessels through the tumour
and has parallels to a recent report demonstrating that zebrafish larval
macrophages associate with blood vessel tips at wounds and are
required for neo-angiogenesis during wound healing (Gurevich
et al., 2018). Potential mechanisms by which tumour macrophages
can stimulate blood vessel growth include the secretion of
pro-angiogenic factors (such as Vegfa, Egf, Fgf2, Cxcl8 and
Cxcl12) to promote the proliferation and migration of endothelial
cells through the graft and also the secretion of enzymes that
stimulate the breakdown of the extracellular matrix (ECM) (such as
uPA or Mmp2 and 9) (Albini et al., 2018). Our data support both of
these possible mechanisms, whereby zebrafish pro-angiogenic
macrophages secrete angiogenic factors (such as Vegfa) and/or
allow ECM breakdown to drive angiogenesis in grafts. To further
elucidate which of these mechanisms are employed by macrophages
in this model, a macrophage-specific knockout of these
pro-angiogenic pathways could be employed (Ablain et al., 2015).
Finally, we show that macrophages are not required for all
VEGFR-mediated graft angiogenesis as the limited vascularisation
of either HEK-293T grafts, which express low levels of VEGFA, or
Fluospheres, which express no VEGFA, is sensitive to VEGFR
inhibition but is not sensitive to macrophage ablation. We propose
that the VEGFR-dependent vascularisation of Fluosphere grafts is
likely due to the local release of VEGFR ligands from tissue
damaged during graft implantation; various cells, including
keratinocytes, are known to secrete VEGF ligands upon
wounding (Brown et al., 1992; Kishimoto et al., 2000; Failla
et al., 2000) and an upregulation of vegfaa has been observed in
zebrafish wounds and granulomas (Gurevich et al., 2018; Marín-
Juez et al., 2016; Oehlers et al., 2015). However, as discussed
previously, the angiogenic response to Fluosphere and HEK-293T
grafts does not require macrophage involvement, either due to a lack
of pro-angiogenic macrophages within these grafts and/or because a
higher level of extrinsic VEGF signalling is required before
macrophage angiogenic function becomes evident.
Our study demonstrates that the angiogenic response observed
within zebrafish VEGFA/Vegfaa-secreting xenografts requires a
macrophage-driven inflammatory response. This expands the utility
of this model as it can now be used to investigate the mechanisms by
which macrophages can promote tumour angiogenesis. A greater
understanding of these processes could help in the development
of treatments for pathologies characterised by inflammatory
angiogenesis, such as tumour angiogenesis, choroidal
neovascularisation, arthritis and inflammatory bowel disease
(Pollard, 2009). Finally, this study also has implications on the use
of this model as a tumour angiogenesis assay: any discoveries made
regarding angiogenesis using this model must be interpreted in the
context of the inflammatory nature of the angiogenic response.
MATERIALS AND METHODS
Zebrafish husbandry and maintenance
All zebrafish (Danio rerio) strains were maintained under standard
husbandry conditions and all studies carried out were approved by the
University of Auckland Animal Ethics Committee. The following
transgenic lines were used in this study: Tg(mpeg1:Gal4FF)gl25 (Ellett
et al., 2011), Tg(UAS-E1b:nsfB-mCherry)c264 (Davison et al., 2007), Tg(-8.
mpx:KalTA4)gl28 (Okuda et al., 2015), Tg(kdrl:EGFP)s843 (Jinn et al.,
2005), Tg(lyz:EGFP)nz117 (Hall et al., 2007) and Tg(mpeg1:EGFP)gl22
(Hall et al., 2013). For convenience, the Tg(mpeg1:Gal4FF)gl25;Tg(UAS-
E1b:nsfB-mCherry)c264 line is referred to as mpeg1:NTR:mCherry and the
Tg(-8.mpx:KalTA4)gl28;Tg(UAS-E1b:nsfB-mCherry)c264 line is referred to
as mpx:NTR:mCherry.
Tissue culture
All cell lines were maintained at 37°C and 5% CO2, and passaged at 95-
100% confluence. The following cell lines were used in this study: MDA-
MB-231-luc D3 H2LN, B16-F1 and HEK-293T. B16-F1 and HEK-293T
were originally obtained from the ATCC, while MDA-MB-231 cells were
obtained from Caliper Life Sciences. MDA-MB-231 and B16-F1 cells were
grown in MEM-alpha media, 10% FBS (Gibco) and 1% pen/strep. HEK-
293T cells were grown in low glucose, pyruvate DMEM, 10% FBS (Gibco)
and 1% pen/strep. All cell lines were tested to be Mycoplasma-negative
using the MycoAlert™ Mycoplasma detection kit (Lonza).
VEGFA secretion assay
Total protein content of the cells was determined by conducting a Pierce™
BCA Protein Assay using the Thermo Scientific kit and protocol. VEGFA
secretion was detected by removing a 25 μl sample of media from a
confluent 4 cm2 dish (containing 500 µl of media) and running it on either
the Mouse or Human Cytokine Magnetic bead panels (MILLIPLEX®). The
concentration of VEGFA in the well media and total protein content for each
Fig. 5. Macrophages are required for effective vegfaa-driven
angiogenesis. (A-D) Confocal images taken at 2 dpi of kdrl:EGFP-expressing
vessels (green) in zebrafish embryos implanted with either HEK-293T (A,B) or
MDA-MB-231 (C,D) xenografts (white dashed line) transfected with either a
control expression vector (A,C) or a vegfaa-expression vector (B,D).
(E) Quantitation of graft vascularisation at 2 dpi, n>17. (F-M) Confocal images
taken at 2 dpi of mpeg1:mCherry-expressing macrophages (red) and kdrl:
EGFP-expressing blood vessels (green) in zebrafish embryos implanted with
either HEK-293T or MDA-MB-231 xenografts (white dashed lines) transfected
with either a control expression vector (F,H,J,L) or a vegfaa-expression
vector (G,I,K,M) that have been injected with either PBS-containing liposomes
(F-I) or clodronate-containing liposomes (J-M). (N) Quantitation of graft
vascularisation at 2 dpi in embryos injected with either PBS-containing or
clodronate-containing liposomes, n>16. (O) Schematic demonstrating how
the proximal, middle and distal sections (marked by dashed red lines) of the
xenograft (blue) were determined by their location with respect to the CCV
(green). (P) Quantitation of vascularisation at 2 dpi in the proximal, middle
and distal regions of vegfaa-expressing HEK-293TorMDA-MB-231 xenografts
implanted into embryos injected with either PBS-containing or clodronate-
containing liposomes, n>19. Error bars represent s.d. n.s, P>0.05; *P<0.05,
**P<0.01 by t-test. Scale bars: 50 µm.
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Fig. 6. See next page for legend.
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cell line was calculated for each well analysed, and VEGFA secretion was
divided by protein content to produce a value of VEGFA secreted
concentration with respect to total protein expression for each cell line,
and the mean between the two samples was plotted on the graph for each
cell line.
vegfaa transfection
Full-length zebrafish vegfaa cDNA was isolated by TRIzol-extraction
(Ambion) of RNA from a 1 dpf zebrafish followed by RT-PCR with
Platinum™ Pfx DNA polymerase (Invitrogen) using zebrafish vegfaa
primers (Forward: 5′-GCTAGCATGAACTTGGTTGTTTATTT-3′,
Reverse: 5′-GCGGCCGCTCATCTTGGCTT-3′). vegfaa was cloned into
the mammalian expression vector pIRES-P (Hobbs et al., 1998), which
contains the puromycin-resistance gene. HEK-293 or MDA-MB-231 cells
were transfected using Lipofectamine 2000 (Invitrogen) and transfected
cells were subsequently maintained inmedia containing 2 µg/ml puromycin.
VEGFA siRNA knockdown
siRNA knockdown was performed on MDA-MB-231 cells using an
anti-VEGF siRNA (Thermo Fisher Scientific, cat.: 4392420), with
scrambled siRNA (Thermo Fisher Scientific, cat.: 4390843) as the
negative control. A total of 150 pmol of siRNA and 7.5 µl of
Lipofectamine RNAiMAX (Invitrogen) were added to 500 µl Opti-MEM
in one well of a 6-well plate and incubated at room temperature for 20 min.
200,000 MDA-MB-231 cells in 2.5 ml of supplemented media (without
antibiotics) were added to thewell and incubated at 37°C. After 24 h the cells
were either harvested for implantation or the transfection media was replaced
with serum-free media in order to assess VEGF knockdown at 48 h.
RT-PCR
RNA was extracted from cell lines using TRIzol (Ambion). Superscript III
Reverse Transcriptase (Invitrogen) was used to synthesise cDNA, and
RT-PCR was conducted using the zebrafish vegfaa primers described above
and human GAPDH primers as a control (Forward: 5′-ACGGGAAGCTT-
GTCATCA-3′, Reverse: 5′-TGGACTCCACGACGTACTCA-3′).
Xenotransplantation
Cells were trypsinised, centrifuged and labelled by resuspending in a 2 ml
solution of either 2 μM CellTracker™ Green (Invitrogen) or 3 µg/ml
Hoechst for 40 or 20 min, respectively, at 37°C. Following labelling, cells
were centrifuged and mixed with 50% LDEV-free Corning® Matrigel®
Basement MembraneMatrix in PBS at a 5:2 ratio of tumour cells:Matrigel®.
This mixture was injected into the perivitelline space of 2-dpf zebrafish
embryos as described (Nicoli and Presta, 2007). The embryos were then
washed and placed in E3 media containing 30 mg/l PTU in E3 and
incubated at 34°C. FluoSpheres® 1 μm Blue (Invitrogen) grafts, were
injected as a 20:1 Fluosphere®:Matrigel® mixture.
Microinjection of clodronate liposomes
PBS or clodronate liposomes (Liposoma) were mixed with a 50% solution
of 0.02-0.04 μm fluoresceinated red carboxylated latex beads (Molecular
Probes) (as an angiography injection marker to identify successfully
injected embryos) in 2% v/v BSA (Sigma-Aldrich) in a 99:1 ratio of
liposomes:beads. This injection mixture was sonicated for 5 s and loaded
into a borosilicate microinjection needle. At 36 hpf, zebrafish embryos were
anaesthetized in a 0.4 mg/ml Tricaine solution and oriented laterally in 2%
w/v methylcellulose. A total of 2 nl of the mixture was pipetted into the
CCV of the embryo and successful injection of liposomes was confirmed by
the appearance of red fluorescence in the bloodstream.
Nitroreductase-mediated cell ablation
To conduct nitroreductase-mediated macrophage ablation, 36 hpf mpeg1:
NTR:mCherry embryos were incubated in either 0.5% DMSO (control)
or 5 mM metronidazole (Sigma-Aldrich) in E3 solution. To conduct
nitroreductase-mediated neutrophil ablation, 36-hpf mpx:NTR:mCherry
embryos were incubated in 0.75% DMSO (control) or 7.5 mM
metronidazole in E3 solution.
Drug treatment
To test the effects of angiogenesis inhibitor drugs, embryos were incubated
in solutions of Tivozanib (AVEO Pharmaceuticals Inc.), SU5402 (Sigma-
Aldrich) or DMSO (control) immediately after graft implantation.
Immunohistochemistry
Embryos were fixed in 4% paraformaldehyde solution in PBS at 4°C
overnight, stored at −20°C in methanol and stained according to a
previously described fluorescence immunohistochemistry protocol
(Turner et al., 2014). The following antibodies were all used at a dilution
of 1/500: mouse anti-mCherry (Clontech) with goat anti-mouse
Alexa-Fluor®-568 secondary (Invitrogen); chicken anti-EGFP (Abcam)
with goat anti-chicken Alexa-Fluor®-488 secondary (Invitrogen) (Du et al.,
2017; Hall et al., 2014).
Confocal imaging
Live and fixed fish were imaged using a Nikon D-Eclipse C1 confocal
scanning microscope by taking optical sections through the graft at 5-µm
intervals according to a previously described protocol (Hall et al., 2009).
Quantitation of graft vascularisation
Graft vascularisation was quantitated using a previously established method
(Astin et al., 2014). Using Volocity image analysis software (Improvision®,
PerkinElmer), the volume of the Hoechst-stained or blue-fluosphere-
containing graft was defined by identifying all blue fluorescent objects
within a 3D area of interest encompassing the entire graft. A minimum
threshold was set for fluorescence intensity (250 units) and object size
(100 µm3) in order to determine which objects would be defined as part of
the graft. The volume of these objects was totalled to give a value for the
graft volume. To determine the volume of EGFP-expressing blood vessels
associated with the graft, the presence of green fluorescence was identified
in a 3D area of interest encompassing all the blue fluorescent objects by
using a minimum green fluorescence intensity of 100 units and a minimum
volume threshold of 100 µm3 to identify green fluorescent objects present in
this region. The volume of green fluorescent objects was totalled to give the
volume of graft-associated vessels, which was divided by graft volume to
give the percentage of graft vascularisation. To measure the graft
vascularisation in different regions of the xenograft, we divided each
xenograft into three equal sections by volume, labelling the region closest to
the CCV as the proximal region, the next region the middle region and the
region furthest from the CCV as the distal region (Fig. 5O). Volocity image
analysis software (Improvision®, PerkinElmer), was used measure the
percentage of graft vascularisation in each section as described above.
Time-lapse imaging
For time-lapse imaging, live fish were imaged using an Olympus FV1000
confocal scanning microscope and the fish were maintained in a Solent
Fig. 6. Macrophages are not required for vascularisation in MDA-MB-231
xenografts depleted of VEGFA. (A) Quantitation of secreted VEGFA levels in
2×105 siRNA-treated cells, n=2. (B,C) Confocal images taken at 2 dpi of kdrl:
EGFP-expressing vessels (green) in zebrafish embryos implanted with
MDA-MB-231 xenografts (white dashed line) transfected with either control (B)
orVEGFA siRNA (C). (D,E) Confocal images taken at 6 hpi ofmpeg1:mCherry-
expressing macrophages (red) and MDA-MB-231 xenografts (blue).
(F,G) Quantitation of graft vascularisation at 2 dpi, n>10 (F), and of graft-
associated macrophages at 6, 24 and 48 hpi, n>4 (G). (H) Quantitation of graft-
associated macrophages at 6, 24 and 48 hpi, in embryos injected with either
PBS-containing or clodronate-containing liposomes, n>5. (I-L) Confocal
images taken at 2 dpi of mpeg1:mCherry-expressing macrophages (red) and
kdrl:EGFP-expressing blood vessels (green) in zebrafish embryos implanted
with MDA-MB-231 xenografts (white dashed lines) transfected with either
control (I,K) or VEGFA (J,L) siRNA that have been injected with either
PBS-containing liposomes (I,J) or clodronate-containing liposomes (K,L).
(M) Quantitation of graft vascularisation at 2 dpi in embryos injected with either
PBS-containing or clodronate-containing liposomes, n>9. Error bars represent
s.d. n.s, P>0.05; *P<0.05; **P<0.01 by either one-way ANOVA (A) or t-test
(F-H,M). Scale bars: 50 µm.
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incubator at 34°C. The xenografts were imaged every 10 min starting from 8
hpi (MDA-MB-231 xenografts) or 24 hpi (B16-F1 xenografts), and
continuing until the experimental endpoint (48 hpi), with optical sections
taken at 8-µm intervals.
Time-lapse analysis
The vessel observed to display the greatest lengthwise growth was chosen
and analysed over the period of the movie during which it displayed fastest
growth (which usually began at around 24 hpi). During this period (between
5 and 7 h for the MDA-MB-231 and between 3 and 5 h for the B16-F1
xenograft), each frame was analysed by defining a circular region of 10-µm
radius centred around the tip of the growing vessel (the angiogenic region)
and a control region of the same size located 25 µm away from the
angiogenic region but within the graft (Fig. 4H). For each frame analysed,
the presence and number of macrophages in each region was counted; for a
macrophage to be scored present in a particular region it had to be in the
same optical z-section(s) as the blood vessel. Tip-cell macrophages were
defined as those that associated with the distal tip of a graft blood vessel for
at least 40 min. The migration path of the tip-cell macrophage was then
tracked for the amount of time that it associated with the tip cell and this
analysis was repeated for the same amount of time during the period
immediately after it had ceased contact with the tip cell.
Statistical analysis
All statistical analysis was performed using GraphPad Prism. The Shapiro–
Wilk test was used to determine normality of data and, depending on the
result, a two-tailed t-test (for normally distributed data) or a Mann–Whitney
test was used to determine significance. F-tests were used to compare
variance in order to determine whether to use Welch’s correction for the
t-tests. When comparing multiple sets of data, the one-way ANOVA with
Dunnett’s multiple comparisons test was used to determine significance of
normal data, while the Kruskal–Wallis test was employed for data that were
not normally distributed.
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